Skip to main content
. Author manuscript; available in PMC: 2019 Jul 13.
Published in final edited form as: ACS Infect Dis. 2018 May 10;4(7):1114–1120. doi: 10.1021/acsinfecdis.8b00052

Table 4.

Antiribosomal Activities (IC50 μg/mL)a and Selectivities

Antiribosomal Activitya
IC50 μg/mL		 Selectivityb
Bacterial Wild-type Mitohybrid Mutant Deafness Mitohybrid Wild-type Mitohybrid Mutant Deafness Mitohybrid
Sisomicin 3 0.01 9.8 0.6 980 60
6′-(2-Hydroxyethyl)sisomicin 10 0.06 59 6.6 983 110
L-HABA Sisomicin 11 0.01 4.7 0.25 470 25
Plazomicin 4 0.06 50 2.8 833 47
Gentamicin 5 0.015 9 0.5 600 33
Tobramycin 6 0.02 15 0.5 750 25
Apramycin 18 0.08 68 38 850 475
a

All values were determined in duplicate using twofold dilution series.

b

Selectivity = eukaryotic/prokaryotic antiribosomal activity